Tag:
Zelboraf
Latest Headlines
Latest Headlines
GSK lands one-two punch in melanoma trial
Data from the small mid-stage trial provide early evidence that GSK's two-drug combo could have an edge over Roche's approved melanoma drug Zelboraf.
Support seen for U.S. plan to speed nods for 'breakthrough' drugs
This year the agency and U.S. lawmakers appear to be supportive of a plan that would help pharma groups race to the market with breakthrough drugs.
New Zelboraf data shows big survival boost
Roche's ( $RHHBY ) new melanoma drug Zelboraf apparently works even better than researchers suspected.
New Zelboraf data shows big survival boost
Roche's ( $RHHBY ) new melanoma drug Zelboraf apparently works even better than researchers suspected.
Roche results spotlight targeted-drug strategy
After a series of Big Pharma letdowns, Roche's ( $RHHBY ) results announcement was a series of positives: An increase in 2011 net income, a sales-growth forecast in the "low to mid-single digits," and
Adding MEK drug to Zelboraf could stymie secondary cancers
When Roche 's melanoma drug Zelboraf won the FDA nod in August, it became the first therapy for the disease targeted at patients with a particular genetic abnormality. Scientists now have found
Roche gets key nod for targeted skin cancer drug en route to EU approval
A standout drug for "personalized" skin cancer treatment has gained a key endorsement from European regulators. Roche ( $RHHBY ) said that the European Medicines Agency backed the targeted melanoma
CHMP gives thumbs up to Roche melanoma drug
The EU's Committee for Medicinal Products for Human Use has recommended that Roche 's Zelboraf be granted full marketing authorization to treat adults with BRAF V600 mutation-positive unresectable or
Roche chief pushes productivity while waiting on new drugs
Roche CEO Severin Schwan ( photo ) is promising big leaps forward, thanks to drugs targeted by companion diagnostics. In an interview with the Wall Street Journal, Schwan pointed to the company's new
Roche melanoma drug wins early FDA nod
The FDA came through with an early approval for Roche's new melanoma drug Zelboraf and the diagnostic test that targets it. The drug works on patients with a BRAF mutation, which amounts to about
